1. Alemtuzumab induction treatment significantly reduced events of biopsy-proven acute rejection (BPAR) when compared with standard basiliximab-based therapy (BBT).
2. Kidney graft function at six months was not significantly different between the two therapy regimes.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Acute antibody-mediated or cellular rejection affects approximately 16% of kidney...